Figure 4.

Effects of selumetinib on quality of life and pain. (A) Number of pediatric patients, their parents, and adult patients who reported improvements (blue), no change (orange), or worsening (gray) in their quality of life between baseline and cycle 26. Total scores and subscores (ie, school, social, emotional, and physical functioning) of quality of life are shown. (B) Duration of pain during the last 24 hours in adult patients. (C) Frequency of pain during the last 24 hours in adult patients. (D) Radial charts showing the scores of 5 fields (tumor volume, QOL score, pain score, FSIQ, processing speed) that were assessed at baseline, first evaluation, and second evaluation.